SEC Tracker
Get the app
JANX · XBRL financial data

Janux Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (JANX's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Research and development12*14151921*25353532*273131
General and administrative6*78188*10101111*111110
Operating income (loss)(16)*(20)(14)(36)(29)*(35)(45)(35)(42)*(34)(32)(31)
Income tax expense (benefit)year only———year only———year only———
Net income (loss)(12)*(15)(6)(28)(20)*(24)(34)(24)(32)*(24)(22)(22)
Earnings per share, basic USD per share(0.25)*(0.30)(0.11)(0.51)(0.36)*(0.38)(0.55)(0.39)(0.51)*(0.39)(0.35)(0.34)
Earnings per share, diluted USD per share(0.25)*(0.30)(0.11)(0.51)(0.36)*(0.38)(0.55)(0.39)(0.51)*(0.39)(0.35)(0.34)
Weighted average shares, basic millions of shares47*49545557*62626262*636363
Weighted average shares, diluted millions of shares47*49545557*62626262*636363

Balance sheet

CSV

Fiscal quarters (JANX's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents19213152743174524852522842
Short-term investments325439632631595940944941914905943904
Accounts receivable018—————————
Prepaid and other current assets5688891099111213
Total current assets3496596626661,0341,0231,0069989761,002983959
Property and equipment, net776555544433
Right-of-use asset212020201919181918181717
Total assets3806896916951,0621,0511,0321,0251,0021,0281,008984
Accounts payable221242335334
Accrued liabilities769131213162218152020
Total current liabilities131112171718212825596054
Lease liability, non-current232322222121202020191818
Total liabilities363334393938424845878072
Accumulated deficit(169)(184)(189)(218)(238)(261)(295)(319)(351)(376)(398)(419)
Total stockholders' equity3446566586561,0231,012991977957942928912
Total liabilities and equity3806896916951,0621,0511,0321,0251,0021,0281,008984
Common shares outstanding (cover page) millions of shares525252525959606061616161

Cash flows

CSV

Fiscal quarters (JANX's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(12)*(15)(6)(28)(20)*(24)(34)(24)(32)*(24)(22)(22)
Stock-based compensation4*66156*1111910*999
Net cash from operating activities(10)*(15)(10)*(2)*(17)*(17)(24)*(13)*(29)*(12)12*(25)*
Purchases of property and equipment1*00*0*0*00*0*0*00*0*
Net cash from investing activities11*(114)(191)*13*34*(340)2*8*30*8(39)*38*
Net cash from financing activities1*3223*2*387*11*0*3*42*1*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Janux Therapeutics429.3(25)*61.2M111.2 quarters 10-QSep 30, 2026
Spyre Therapeutics83not reported(77)*95.0M15.7 quarters 10-QSep 30, 2026
Schrodinger24764(48)*not reported10.9 quarters 10-QSep 30, 2026
Mannkind41102(35)*321.6M4.2 quarters 10-QSep 30, 2026
Novavax22268(94)*165.0M9.4 quarters 10-QSep 30, 2026
Harrow8471(9.8)*37.5M8.6 quarters 10-QJun 30, 2026
Aurinia Pharmaceuticals468446*134.0M— 10-QSep 30, 2026
Neogen17222313218.3M— 10-QAug 31, 2026
Innoviva58110642*71.1M— 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.